Study Stopped
Poor recruitment
Dietary Histone Deacetylase Inhibitors (HDAC)
Dietary Histone Deacetylase (HDAC) Inhibitors
1 other identifier
interventional
23
1 country
1
Brief Summary
This pilot, three-week study will help scientists understand more about how the foods people eat can modify histone deacetylases, enzymes the body produces naturally. Broccoli sprout extract (BSE) and garlic oil are thought to modify these enzymes. The purpose of this study is to see if taking broccoli sprout extract alone, garlic oil alone, or broccoli sprout extract and garlic oil together, can decrease the action of histone deacetylase (HDAC) and turn on genes in white blood cells. There will be 80 people in this study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2013
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2012
CompletedFirst Posted
Study publicly available on registry
March 2, 2012
CompletedStudy Start
First participant enrolled
February 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedResults Posted
Study results publicly available
September 10, 2015
CompletedApril 30, 2019
April 1, 2019
10 months
February 17, 2012
June 1, 2015
April 8, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Cmax of Sulforaphane and Its Metabolites in Blood
The levels of "Sulforaphane and its metabolites (combined)" in blood was measured using Liquid Chromatrography-Mass Spectrometry (LC-MS) methods. Cmax (mean +/- SD) values are shown in the "Outcome Measure Data Table".
Before breakfast (0 hours) and 1, 3 and 6 hours after breakfast & pills on Days 1 & 7, and before breakfast on Days 8, 9 and 14.
Tmax of Sulforaphane and Its Metabolites in Blood
The levels of "Sulforaphane and its metabolites (combined)" in blood was measured using Liquid Chromatrography-Mass Spectrometry (LC-MS) methods. The time to achieve highest plasma concentration (Tmax) is shown in the "Outcome Measure Data Table".
Before breakfast (0 hours) and 1, 3 and 6 hours after breakfast & pills on Days 1 & 7, and before breakfast on Days 8, 9 and 14.
Secondary Outcomes (1)
Histone Acetylation
6 h
Study Arms (4)
BSE placebo & garlic oil placebo
PLACEBO COMPARATORTwo BSE placebo capsules and one garlic oil placebo capsule per day for seven days
garlic oil plus BSE placebo
ACTIVE COMPARATORone garlic oil capsule plus 2 BSE placebo capsules per day for seven days
BSE plus garlic oil placebo
ACTIVE COMPARATORtwo BSE capsules plus one garlic oil placebo capsule per day for seven days
BSE & Garlic Oil
ACTIVE COMPARATORtwo BSE and one garlic oil capsule per day for seven days
Interventions
2 pills = 0 micromoles of Sulforaphane/day
1 pill = 30 mg garlic oil/day
2 pills = 200 micromoles of Sulforaphane/day
1 pill = 0 mg garlic oil/day
Eligibility Criteria
You may qualify if:
- age: 20 and older
- body mass index 19-30 kg/sq m
- willingness to maintain normal exercise and activity patterns
- willingness to avoid cruciferous vegetables and garlic and related foods (onion etc.) 1 week before and 2 weeks during the trial for a total of 3 weeks
You may not qualify if:
- tobacco use within the past three months
- engaging in aerobic activity more than 6 hours per week
- being vegetarian or having other restrictive dietary requirements
- consuming \>3 alcoholic beverages/day or \>10 per week
- having history of diabetes or uremia or other known metabolic disease
- participating in another dietary study within the past three months
- for women, being pregnant or breastfeeding
- gastrointestinal diseases that could increase gut permeability, including Crohn's disease, ulcerative colitis, gastritis
- taking dietary supplements other than those given in the study
- abnormal liver function, CBC, or thyroid values
- individuals taking any drug or medication, prescription or over the counter, including Isoniazid, Saquinavir, Warfarin, Cyclosporine, Acetaminophen, Oxazepam, medications used for HIV/ AIDS, blood clotting, birth control pills, fish oil and medications metabolized by CYPs (CYP1A2, CYP2E1 and CYP3A4) during the dosing period of 1 week and 48 h prior to and after dosing. Exceptions may be made by the study MD and the PI if in their opinion a medication will not interfere with the scientific validity of the study. The study MD will evaluate a medication on a case-by-case basis to determine that efficacy and safety are not adversely affected.
- Individuals who are known to have problems with blood clotting or increased bleeding, including hemophiliacs or anyone recently undergoing or recovering from a surgical procedure.
- soy or garlic allergy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Oregon State University
Corvallis, Oregon, 97331, United States
Related Publications (1)
Rajendran P, Dashwood WM, Li L, Kang Y, Kim E, Johnson G, Fischer KA, Lohr CV, Williams DE, Ho E, Yamamoto M, Lieberman DA, Dashwood RH. Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon. Clin Epigenetics. 2015 Sep 18;7(1):102. doi: 10.1186/s13148-015-0132-y. eCollection 2015.
PMID: 26388957RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Early termination (23/80) due to small numbers of subjects recruited.
Results Point of Contact
- Title
- Rod Dashwood
- Organization
- Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston TX
Study Officials
- PRINCIPAL INVESTIGATOR
Roderick Dashwood, PhD
Texas A&M University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director Center for Epigenetics & Disease Prevention
Study Record Dates
First Submitted
February 17, 2012
First Posted
March 2, 2012
Study Start
February 1, 2013
Primary Completion
December 1, 2013
Study Completion
December 1, 2013
Last Updated
April 30, 2019
Results First Posted
September 10, 2015
Record last verified: 2019-04